Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Yu Fujiwara MD

Yu Fujiwara MD profile photo picture

Assistant Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Medicine Hematology Oncology

Publications (63)

  • Stereotactic body radiation therapy enriches mediators of humoral immune activity in metastatic renal cell carcinoma. (Salgia NJ, Khan A, Fujiwara Y, Long M, Twoey GC, Leatt K, Chow J, Abrams SI, Schwaab T, Singh AK, Muhitch JB) J Immunother Cancer 2026 Oct 08;14(10) PMID: 42849919 10/08/2026    
  • Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards. (Fujiwara Y, Kato S, Kurzrock R) Hematol Oncol Clin North Am 2026 Oct;40(5):685-704 PMID: 42686322 SCOPUS ID: 2-s2.0-105049040188 09/03/2026    
  • Safety of immune checkpoint modulators beyond PD-1/PD-L1 and CTLA-4 in solid tumors: a meta-analysis. (Fujiwara Y, Okamura Y, Ramesh M, Tehrani YF, Aburaki R, Takahashi T, Ahluwalia MS, Mukherjee S) JNCI Cancer Spectr 2026 Jul 07;10(4) PMID: 42316819 PMCID: PMC13375266 SCOPUS ID: 2-s2.0-105045150513 06/19/2026    
  • Interleukin-2 transcriptomic expression correlates with prolonged survival and with GNAS alterations in patients with advanced cancers. (Ahmed J, Nishizaki D, Fujiwara Y, DePietro P, Jensen TJ, McFall T, Kato S, Kurzrock R) ESMO Open 2026 Jun;11(6):107768 PMID: 42263481 PMCID: PMC13272506 SCOPUS ID: 2-s2.0-105041408368 06/10/2026    
  • Incidence and treatment-modifying impact of immune checkpoint inhibitor-associated peripheral edema: a systematic review and meta-analysis. (Markus A, Tsuchiya K, Takahashi T, MBBCh EE, Koseki M, Nishimura Y, Rohs NC, Fujiwara Y) JNCI Cancer Spectr 2026 Jul 07;10(4) PMID: 42234870 PMCID: PMC13428319 SCOPUS ID: 2-s2.0-105046116271 06/03/2026    
  • PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes. (Marinelli D, Citarella F, Torchia A, Pannu S, Aijaz A, Sisca L, Russano M, Fujiwara Y, Takada K, Nassar AH, Banna GL, Ricciuti B, Brunetti L, Santo V, Passaro A, Saw SPL, Li MSC, Addeo A, Ferrara R, Di Maio M, Mountzios G, Santini D, Maugeri-Saccà M, Vincenzi B, Acker F, Reckamp KL, Cappuzzo F, Naqash AR, Cortellini A) Cancer Treat Rev 2026 Jun;147:103159 PMID: 42224849 SCOPUS ID: 2-s2.0-105040675658 06/02/2026       2 Citations
  • Orchestration of B and T cells predicts prolonged survival after cancer immune checkpoint inhibitor therapy. (Fujiwara Y, Kato S, Nishizaki D, Miyashita H, Lee S, Jensen TJ, DePietro P, Seager RJ, Ikeda S, Kurzrock R) NPJ Precis Oncol 2026 Apr 28;10(1) PMID: 42049950 PMCID: PMC13328500 SCOPUS ID: 2-s2.0-105043594073 04/29/2026    
  • Infusion-Related Reactions from Immune Checkpoint Inhibitors in Solid Tumors: A Proportional and Network Meta-Analysis. (Fujiwara Y, Takahashi T, Tsuchiya K, Koseki M, Markus A, Elias E, Nishimura Y, Puzanov I) Target Oncol 2026 May;21(3):327-336 PMID: 41996022 SCOPUS ID: 2-s2.0-105035865970 04/18/2026    
  • Class II Major Histocompatibility Complex Transactivator (CIITA): A Master MHC-II Regulator Impacting Cancer and Beyond. (Low SK, Fujiwara Y, Nishizaki D, Kato S, Kurzrock R) J Immunother Precis Oncol 2026 Apr;9(2):36-45 PMID: 41994077 PMCID: PMC13078950 SCOPUS ID: 2-s2.0-105043493651 04/17/2026       1 Citation
  • Evolving Trends in Latin American Participation in Global Oncology Clinical Trials: A Decade of Phase III Activity (2013-2022). (Paredes de la Fuente R, Karol AB, Markus A, Argulian A, Omori R, Fujiwara Y, Joshi H, Doroshow DB, Galsky MD) JCO Glob Oncol 2026 Feb;12:e2500411 PMID: 41719503 SCOPUS ID: 2-s2.0-105030785909 02/20/2026       1 Citation
  • Flare incidences of pre-existing rheumatologic diseases in patients with solid tumors receiving immune checkpoint inhibitors: A systematic review and meta-analysis. (Yamada K, Matsui T, Takahashi T, Nishimura Y, Fujiwara Y) Semin Arthritis Rheum 2026 Apr;77:152938 PMID: 41643573 SCOPUS ID: 2-s2.0-105033514371 02/06/2026       1 Citation
  • Perioperative chemoimmunotherapy for patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. (Omori R, Fujiwara Y, Tokunaga K, Sato T, Mukherjee S) JNCI Cancer Spectr 2026 Jan 09;10(1) PMID: 41581222 PMCID: PMC12878334 SCOPUS ID: 2-s2.0-105029679119 01/25/2026       2 Citations
  • CD40 transcriptomic expression patterns across malignancies: implications for clinical trials of CD40 agonists. (Uehara Y, Nishizaki D, Fujiwara Y, Miyashita H, Lee S, Pabla S, DePietro P, Ko H, Jensen TJ, Sicklick JK, Kato S, Kurzrock R) Cancer Immunol Immunother 2025 Nov 03;74(12):359 PMID: 41182434 PMCID: PMC12583269 SCOPUS ID: 2-s2.0-105020738477 11/03/2025       3 Citations
  • The Efficacy and Safety of Beta-blockers and Immune Checkpoint Inhibitors in Patients with Cancer: A Systematic Review and Meta-analysis. (Tokunaga K, Fujiwara Y, Omori R, Sato T, Ahluwalia MS, Mukherjee S) Target Oncol 2025 Nov;20(6):893-905 PMID: 41176581 PMCID: PMC12669259 SCOPUS ID: 2-s2.0-105020459707 11/02/2025       11 Citations
  • Documentation of patient withdrawals, retention strategies, and postwithdrawal data practices in cancer clinical trials. (Karol AB, Paredes R, Argulian A, Joshi H, Weintraub L, Oguntuyo K, Miller J, Fujiwara Y, Doroshow DB, Galsky MD) Cancer 2025 Oct 01;131(19):e70106 PMID: 41004397 SCOPUS ID: 2-s2.0-105017077982 09/26/2025    
  • Outcomes of immune checkpoint inhibitor rechallenge in relapsed/refractory Hodgkin lymphoma. (Nishimura Y, Han Y, Toumeh N, Janda G, Fujiwara Y, Durani U, Nowakowski GS, Paludo J, Ansell SM, Abeykoon JP) Blood Neoplasia 2025 Aug;2(3):100134 PMID: 40809195 PMCID: PMC12346057 SCOPUS ID: 2-s2.0-105012391612 08/14/2025       2 Citations
  • Immune checkpoint inhibitors as neoadjuvant therapy for resectable non-small cell lung cancer: a systematic review and network meta-analysis. (Aburaki R, Fujiwara Y, Haketa S, Horita N) J Natl Cancer Inst 2025 Nov 01;117(11):2191-2201 PMID: 40701555 SCOPUS ID: 2-s2.0-105021092734 07/24/2025       5 Citations
  • Biological and Clinical Insight into the Prevention and Management of Metastatic Renal Cell Carcinoma with a Sarcomatoid Component. (Salgia NJ, Fujiwara Y, Xu B, George S, Muhitch JB, Kauffman EC) Eur Urol Focus 2025 May;11(3):421-424 PMID: 40517094 SCOPUS ID: 2-s2.0-105008030354 06/15/2025       2 Citations
  • Arthralgia in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis. (Nishimura Y, Estaris J, Koseki M, Elias E, Chesta F, Takaoka K, Shao T, Horita N, Fujiwara Y) Immunotherapy 2025 Apr;17(6):437-446 PMID: 40337868 PMCID: PMC12091910 SCOPUS ID: 2-s2.0-105004470295 05/08/2025       1 Citation
  • Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: A Phase II Study. (Mukherjee S, Fujiwara Y, Fountzilas C, Pattnaik H, Chatley S, Vadehra D, Kukar M, Attwood K, George A, Advani S, Yu H, Catalfamo K, Brown A, Spickard E, Fungtammasan A, George S, Liao CY, Iyer R, Hatoum H) Cancer Med 2025 Apr;14(7):e70835 PMID: 40200573 PMCID: PMC11978735 SCOPUS ID: 2-s2.0-105002242080 04/09/2025       1 Citation
  • Encouraging co-targeting of immunoregulatory molecules in cancer treatment. (Sato T, Fujiwara Y) Immunotherapy 2025 Feb;17(2):67-70 PMID: 39910808 PMCID: PMC11901359 SCOPUS ID: 2-s2.0-85217161255 02/06/2025       1 Citation
  • Prognosis and tumor microenvironment in pseudohypoxic pheochromocytoma/paraganglioma. (Ohmoto A, Shigematsu Y, Saito R, Dobashi A, Fujiwara Y, Togashi Y, Yonese J, Inamura K, Takahashi S) Virchows Arch 2025 May;486(5):983-990 PMID: 39694932 SCOPUS ID: 2-s2.0-85212441118 12/19/2024       6 Citations
  • Safety and Efficacy of Osimertinib in Patients With Non-Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis. (Priantti JN, Fujiwara Y, Aquino de Moraes FC, Michelon I, Castro C, Leighl NB, Cavalcante L, Addeo A, Bar J, Horita N, Cortellini A, Nassar AH, Vilbert M, Naqash AR) JCO Precis Oncol 2024 Nov;8:e2400331 PMID: 39576954 SCOPUS ID: 2-s2.0-85210950081 11/22/2024       9 Citations
  • Pancreatitis in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. (Koseki M, Nishimura Y, Elias E, Estaris J, Chesta F, Takaoka K, Shao T, Horita N, Fujiwara Y) Target Oncol 2024 Nov;19(6):867-877 PMID: 39392549 SCOPUS ID: 2-s2.0-85206641156 10/11/2024       7 Citations
  • Surgical and safety outcomes in patients with non-small cell lung cancer receiving neoadjuvant chemoimmunotherapy versus chemotherapy alone: A systematic review and meta-analysis. (Aburaki R, Fujiwara Y, Chida K, Horita N, Nagasaka M) Cancer Treat Rev 2024 Dec;131:102833 PMID: 39369455 SCOPUS ID: 2-s2.0-85205498931 10/06/2024       24 Citations
  • Heterogeneity in Methods of Estimating Kidney Function for Cancer Clinical Trial Eligibility. (Karol AB, Paredes R, Fujiwara Y, Argulian A, Joshi H, Abramson M, Galsky MD) JAMA Netw Open 2024 Sep 03;7(9):e2433387 PMID: 39283642 PMCID: PMC11406393 SCOPUS ID: 2-s2.0-85204417926 09/17/2024       2 Citations
  • Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC. (Nassar AH, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung JM, Lin JJ, Liu Y, Lin SH, Parikh K, Sridhar A, Shakya P, Dilling TJ, Kaldas D, Gray JE, Lobachov A, Bar J, Luders H, Grohe C, Gupta S, Leal T, Fitzgerald B, Crowley F, Fujiwara Y, Marron TU, Wilgucki M, Reuss J, Chen L, Sankar K, Aredo JV, Neal JW, Wakelee HA, Thummalapalli R, Yu H, Whitaker R, Velazquez A, Ragavan M, Cortellini A, Kwiatkowski DJ, Naqash AR, Goldberg SB, Kim SY) J Thorac Oncol 2025 Jan;20(1):109-118 PMID: 39260522 PMCID: PMC12874404 SCOPUS ID: 2-s2.0-85204883398 09/12/2024       22 Citations
  • Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis. (Karol AB, Fujiwara Y, D'Ovidio T, Baldwin E, Joshi H, Doroshow DB, Galsky MD) Immunotherapy 2024;16(12):829-840 PMID: 39155854 PMCID: PMC11457654 SCOPUS ID: 2-s2.0-85201548840 08/19/2024       11 Citations
  • Endocrine adverse events in patients with cancer receiving perioperative immune checkpoint blockade: a meta-analysis of randomized controlled trials. (Zhou S, Horita N, Shao T, Harrington M, Fujiwara Y) Ther Adv Med Oncol 2024;16:17588359241257874 PMID: 38845790 PMCID: PMC11155360 SCOPUS ID: 2-s2.0-85196424320 06/07/2024       5 Citations
  • High indoleamine 2,3-dioxygenase transcript levels predict better outcome after front-line cancer immunotherapy. (Fujiwara Y, Kato S, Nishizaki D, Miyashita H, Lee S, Nesline MK, Conroy JM, DePietro P, Pabla S, Lippman SM, Kurzrock R) iScience 2024 Apr 19;27(4):109632 PMID: 38632994 PMCID: PMC11022045 SCOPUS ID: 2-s2.0-85189797143 04/18/2024       10 Citations
  • C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis. (Fujiwara Y, Karol AB, Joshi H, Reford E, Izadmehr S, Doroshow DB, Galsky MD) Crit Rev Oncol Hematol 2024 May;197:104352 PMID: 38614269 PMCID: PMC11219184 SCOPUS ID: 2-s2.0-85190264736 04/14/2024       18 Citations
  • Accurately addressing double-arm-zero-events studies in meta-analyses - Authors' reply. (Fujiwara Y, Horita N, Naqash AR) Lancet Oncol 2024 Mar;25(3):e93 PMID: 38423061 SCOPUS ID: 2-s2.0-85186304844 03/01/2024       2 Citations
  • Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards. (Fujiwara Y, Kato S, Kurzrock R) Surg Oncol Clin N Am 2024 Apr;33(2):197-216 PMID: 38401905 PMCID: PMC10894322 SCOPUS ID: 2-s2.0-85180341239 02/25/2024       18 Citations
  • The Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiovascular Outcomes in Patients With Cancer: A Systematic Review and Meta-Analysis. (Agarwal S, Qamar U, Fujiwara Y, Guha A, Naqash AR, Yang EH, Addison D, Barac A, Asad ZUA) Am J Cardiol 2024 Apr 01;216:87-90 PMID: 38373679 PMCID: PMC11345618 SCOPUS ID: 2-s2.0-85186561029 02/20/2024       8 Citations
  • Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. (Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB) J Thorac Oncol 2024 Jun;19(6):928-940 PMID: 38278303 SCOPUS ID: 2-s2.0-85186574736 01/27/2024       50 Citations
  • Association of Survival With Immune-Related Adverse Events-Time to Consider the Duration of Treatment. (Fujiwara Y, Cortellini A, Naqash AR) JAMA Dermatol 2024 Mar 01;160(3):368-369 PMID: 38265810 SCOPUS ID: 2-s2.0-85183915660 01/24/2024    
  • Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. (Horita N, Fujiwara Y) N Engl J Med 2024 Jan 18;390(3):287 PMID: 38231634 SCOPUS ID: 2-s2.0-85182767236 01/17/2024       16 Citations
  • Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials. (Fujiwara Y, Horita N, Adib E, Zhou S, Nassar AH, Asad ZUA, Cortellini A, Naqash AR) Lancet Oncol 2024 Jan;25(1):62-75 PMID: 38012893 SCOPUS ID: 2-s2.0-85178215657 11/28/2023       79 Citations
  • The Geriatric Nutritional Risk Index as a prognostic factor in older adult patients with locally advanced head and neck cancer receiving definitive chemoradiotherapy with tri-weekly cisplatin. (Fujiwara Y, Sato Y, Hayashi N, Fukuda N, Wang X, Nakano K, Ohmoto A, Urasaki T, Ono M, Tomomatsu J, Toshiyasu T, Mitani H, Takahashi S) J Geriatr Oncol 2023 Jun;14(5):101523 PMID: 37229881 SCOPUS ID: 2-s2.0-85159847451 05/26/2023       12 Citations
  • First-line therapy for elderly patients with advanced renal cell carcinoma in the immuno-oncology era: a network meta-analysis. (Fujiwara Y, Miyashita H, Liaw BC) Cancer Immunol Immunother 2023 Jun;72(6):1355-1364 PMID: 36495342 PMCID: PMC10991449 SCOPUS ID: 2-s2.0-85143584677 12/11/2022       7 Citations
  • Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy. (Fujiwara Y, Kato S, Nesline MK, Conroy JM, DePietro P, Pabla S, Kurzrock R) Cancer Treat Rev 2022 Nov;110:102461 PMID: 36058143 PMCID: PMC12187009 SCOPUS ID: 2-s2.0-85137057610 09/05/2022       293 Citations
  • Targeting KRAS: Crossroads of Signaling and Immune Inhibition. (Kato S, Fujiwara Y, Hong DS) J Immunother Precis Oncol 2022 Aug;5(3):68-78 PMID: 36034582 PMCID: PMC9390702 SCOPUS ID: 2-s2.0-85137043325 08/30/2022       13 Citations
  • Clinical Characteristics and Outcomes of Gastritis Associated With Immune Checkpoint Inhibitors: Scoping Review. (Obeidat A, Silangcruz K, Kozai L, Wien E, Fujiwara Y, Nishimura Y) J Immunother 2022 Oct 01;45(8):363-369 PMID: 35972801 SCOPUS ID: 2-s2.0-85137745878 08/17/2022       18 Citations
  • Platinum-doublet chemotherapy for advanced gastroenteropancreatic neuroendocrine carcinoma: a systematic review and meta-analysis. (Ohmoto A, Fujiwara Y, Horita N, Nakano K, Takahashi S) Discov Oncol 2022 May 30;13(1):40 PMID: 35635617 PMCID: PMC9151982 SCOPUS ID: 2-s2.0-85130886213 06/01/2022       8 Citations
  • Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials. (Fujiwara Y, Horita N, Harrington M, Namkoong H, Miyashita H, Galsky MD) Cancer Immunol Immunother 2022 Dec;71(12):2837-2848 PMID: 35471602 PMCID: PMC10992785 SCOPUS ID: 2-s2.0-85128810479 04/27/2022       13 Citations
  • Adverse events induced by nivolumab and ipilimumab combination regimens. (Somekawa K, Horita N, Kaneko A, Tagami Y, Fukuda N, Matsumoto H, Namkoong H, Fujiwara Y, Minegishi K, Fukumoto T, Watanabe K, Hara Y, Kobayashi N, Kaneko T) Ther Adv Med Oncol 2022;14:17588359211058393 PMID: 35173819 PMCID: PMC8841925 SCOPUS ID: 2-s2.0-85120676433 02/18/2022       19 Citations
  • Clinical Impact of Cachexia in Head and Neck Cancer Patients Who Received Chemoradiotherapy. (Hayashi N, Sato Y, Fujiwara Y, Fukuda N, Wang X, Nakano K, Urasaki T, Ohmoto A, Ono M, Tomomatsu J, Sato Y, Mitani H, Toshiyasu T, Takahashi S) Cancer Manag Res 2021;13:8377-8385 PMID: 34795523 PMCID: PMC8593206 SCOPUS ID: 2-s2.0-85119134458 11/20/2021       18 Citations
  • Self-assessment of health status among lesbian, gay, and bisexual cancer survivors in the United States. (Li Y, Theodoropoulos N, Fujiwara Y, Xie H, Wang Q) Cancer 2021 Dec 15;127(24):4594-4601 PMID: 34406650 SCOPUS ID: 2-s2.0-85112757266 08/19/2021       9 Citations
  • The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials. (Fujiwara Y, Horita N, Namkoong H, Galsky MD) Eur J Cancer 2021 Jun;150:168-178 PMID: 33906099 SCOPUS ID: 2-s2.0-85104742463 04/28/2021       22 Citations
  • Efficacy of Paclitaxel-based Chemotherapy After Progression on Nivolumab for Head and Neck Cancer. (Sato Y, Fukuda N, Fujiwara YU, Wang X, Urasaki T, Ohmoto A, Nakano K, Ono M, Tomomatsu J, Mitani H, Takahashi S) In Vivo 2021;35(2):1211-1215 PMID: 33622923 PMCID: PMC8045096 SCOPUS ID: 2-s2.0-85101907263 02/25/2021       20 Citations
  • Clinical features and outcomes of metastatic pheochromocytoma treated by cytotoxic chemotherapy. (Fujiwara Y, Ohmoto A, Fukuda N, Wang X, Urasaki T, Hayashi N, Sato Y, Nakano K, Yunokawa M, Ono M, Tomomatsu J, Yuasa T, Yonese J, Takahashi S) Endocr J 2021 Jun 28;68(6):671-681 PMID: 33518616 SCOPUS ID: 2-s2.0-85109307695 02/02/2021       8 Citations
  • Changes in Treatment Behavior during the COVID-19 Pandemic among Patients at a Cancer Hospital. (Sato Y, Fujiwara Y, Fukuda N, Hayama B, Ito Y, Ohno S, Takahashi S, COVID-19 Working Group of The Cancer Institute Hospital of Japanese Foundation for Cancer Research) Cancer Cell 2021 Feb 08;39(2):130-131 PMID: 33465338 PMCID: PMC7787502 SCOPUS ID: 2-s2.0-85100091826 01/20/2021       11 Citations
  • A severe case of thrombocytopenia, anasarca, fever, renal insufficiency or reticulin fibrosis, and organomegaly syndrome with myocardial and skeletal muscle calcification despite hypocalcemia: a case report. (Minomo S, Fujiwara Y, Sakashita S, Takamura A, Nagata K) J Med Case Rep 2021 Jan 06;15(1):3 PMID: 33402219 PMCID: PMC7786502 SCOPUS ID: 2-s2.0-85098684196 01/07/2021       9 Citations
  • Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients. (Fukuda N, Yunokawa M, Fujiwara Y, Wang X, Ohmoto A, Hayashi N, Urasaki T, Sato Y, Nakano K, Ono M, Tomomatsu J, Mitani H, Takahashi S) Cancer Rep (Hoboken) 2021 Apr;4(2):e1322 PMID: 33295110 PMCID: PMC8451378 SCOPUS ID: 2-s2.0-85097298193 12/10/2020       10 Citations
  • Tumor growth rate as a prognostic factor for metastatic or recurrent adenoid cystic carcinoma of the head and neck patients treated with carboplatin plus paclitaxel. (Fukuda N, Fujiwara Y, Wang X, Ohmoto A, Urasaki T, Hayashi N, Sato Y, Nakano K, Yunokawa M, Ono M, Tomomatsu J, Takahashi S) Eur Arch Otorhinolaryngol 2021 Aug;278(8):3037-3043 PMID: 33219858 SCOPUS ID: 2-s2.0-85096379729 11/22/2020       5 Citations
  • Screening for COVID-19 in Symptomatic Cancer Patients in a Cancer Hospital. (Fujiwara Y, Sato Y, Wang X, Oikado K, Sato Y, Fukuda N, Enokida T, Takeda K, Ohkushi D, Hayama B, Egi Y, Tokai Y, Yamada Y, Nakajima Y, Kubota M, Haruki S, Shimizu T, Uchida Y, Utsugi K, Ito Y, Ohno S, Takahashi S, Tsuchida T, COVID-19 Working Group of The Cancer Institute Hospital of Japanese Foundation for Cancer Research) Cancer Cell 2020 Nov 09;38(5):609-610 PMID: 33064994 PMCID: PMC7531558 SCOPUS ID: 2-s2.0-85094966240 10/17/2020       6 Citations
  • An extragonadal germ cell tumor with dermatomyositis: A case report and literature review. (Fujiwara Y, Fukuda N, Ohmoto A, Nakano K, Ono M, Taira S, Torii J, Takamatsu M, Takahashi S) Mol Clin Oncol 2020 Nov;13(5):60 PMID: 32953114 PMCID: PMC7484733 SCOPUS ID: 2-s2.0-85090953162 09/22/2020       4 Citations
  • Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Anaplastic Thyroid Cancer Treated With Lenvatinib. (Fukuda N, Toda K, Fujiwara YU, Wang X, Ohmoto A, Urasaki T, Hayashi N, Sato Y, Nakano K, Yunokawa M, Ono M, Tomomatsu J, Mitani H, Takahashi S) In Vivo 2020;34(5):2859-2864 PMID: 32871825 PMCID: PMC7652499 SCOPUS ID: 2-s2.0-85090181971 09/03/2020       31 Citations
  • Portal Vein Thrombosis in Metastatic Colorectal Cancer During FOLFIRI-bevacizumab Chemotherapy Successfully Treated with Apixaban. (Fujiwara Y, Yamaguchi T, Nakane M) Intern Med 2021 Jan 01;60(1):53-57 PMID: 32788527 PMCID: PMC7835470 SCOPUS ID: 2-s2.0-85099080134 08/14/2020       5 Citations
  • Granulocyte Colony-Stimulating Factor-Associated Aortitis: Treatment Suggestion for This Complication. (Fujiwara Y, Yamaguchi T, Nakane M) JCO Oncol Pract 2021 Jan;17(1):57-58 PMID: 32644903 SCOPUS ID: 2-s2.0-85099774267 07/10/2020       5 Citations
  • A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy. (Fujiwara Y, Mittra A, Naqash AR, Takebe N) Cancer Drug Resist 2020;3(3):252-275 PMID: 35582437 PMCID: PMC8992481 SCOPUS ID: 2-s2.0-85096472096 06/18/2020       75 Citations
  • Multiple osteolytic bone and lung metastases from prostate cancer including small cell carcinoma with marked increases in CEA and Pro-GRP. (Okamura S, Fujiwara Y, Nagata K) Urol Case Rep 2019 May;24:100883 PMID: 31211092 PMCID: PMC6562363 SCOPUS ID: 2-s2.0-85067172612 06/19/2019       4 Citations
  • The first case of thrombocytopenia, anasarca, fever, renal impairment or reticulin fibrosis, and organomegaly (TAFRO) syndrome with unilateral adrenal necrosis: a case report. (Fujiwara Y, Ito K, Takamura A, Nagata K) J Med Case Rep 2018 Oct 08;12(1):295 PMID: 30293532 PMCID: PMC6174561 SCOPUS ID: 2-s2.0-85054462670 10/09/2018       15 Citations
    • Last update: 10/09/2026